MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells

被引:49
作者
Park, Jehyun [1 ]
Ryu, Dong-Ryeol [2 ]
Li, Jin Ji [1 ,3 ]
Jung, Dong-Sub [1 ]
Kwak, Seung-Jae [1 ]
Lee, Sun Ha [1 ]
Yoo, Tae-Hyun [1 ]
Han, Seung Hyeok [1 ]
Lee, Jung Eun [1 ]
Kim, Dong Ki [1 ]
Moon, Sung Jin [1 ]
Kim, Kunhong [4 ]
Han, Dae Suk [1 ]
Kang, Shin-Wook [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea
[2] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[3] YanBian Univ Med Coll, Affiliated Hosp, Dept Internal Med, Nephrol & Dialysis Unit, JiLin, Peoples R China
[4] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 120752, South Korea
关键词
diabetic nephropathy; monocyte chemoattractant protein-1; transforming growth factor-beta 1; extracellular matrix;
D O I
10.1152/ajprenal.00547.2007
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine that plays an important role in the recruitment of macrophages. Although previous studies have demonstrated the importance of MCP-1 in the pathogenesis of diabetic nephropathy (DN) in terms of inflammation, the role of MCP-1 and its receptor (C-C chemokine receptor 2; CCR2) in extracellular matrix (ECM) accumulation under diabetic conditions has been largely unexplored. This study was undertaken to investigate the functional role of the MCP-1/CCR2 system in high glucose-induced ECM (fibronectin and type IV collagen) protein expression in cultured mesangial cells (MCs). Mouse MCs were exposed to medium containing 5.6 mM glucose (NG), NG + 24.4 mM mannitol (NG + M), or 30 mM glucose (HG) with or without mutant MCP-1 (mMCP-1), CCR2 small interfering (si) RNA, or CCR2 inhibitor (RS102895). To examine the relationship between MCP-1 and transforming growth factor (TGF)-beta 1, MCs were also treated with TGF-beta 1 (2 ng/ml) with or without mMCP-1 or CCR2 siRNA. Transient transfection was performed with Lipofectamine 2000 for 24 h. Cell viability was determined by an MTT assay, mouse and human MCP-1 and TGF-beta 1 levels by ELISA, and CCR2 and ECM protein expression by Western blotting. Transfections of mMCP-1 and CCR2 siRNA increased human MCP-1 levels and inhibited CCR2 expression, respectively. HG-induced ECM protein expression and TGF-beta 1 levels were significantly attenuated by mMCP-1, CCR2 siRNA, and RS102895 (P < 0.05). MCP-1 directly increased ECM protein expression, and this increase was inhibited by an anti-TGF-beta 1 antibody. In addition, TGF-beta 1-induced ECM protein expression was significantly abrogated by the inhibition of the MCP-1/CCR2 system (P < 0.05). These results suggest that an interaction between the MCP-1/CCR2 system and TGF-beta 1 may contribute to ECM accumulation in DN.
引用
收藏
页码:F749 / F757
页数:9
相关论文
共 40 条
[1]   Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [J].
Banba, N ;
Nakamura, T ;
Matsumura, M ;
Kuroda, H ;
Hattori, Y ;
Kasai, K .
KIDNEY INTERNATIONAL, 2000, 58 (02) :684-690
[2]  
Bartoli C, 2001, ACTA NEUROPATHOL, V102, P385
[3]   MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF 2 MONOCYTE CHEMOATTRACTANT PROTEIN-1 RECEPTORS REVEALS ALTERNATIVE SPLICING OF THE CARBOXYL-TERMINAL TAILS [J].
CHARO, IF ;
MYERS, SJ ;
HERMAN, A ;
FRANCI, C ;
CONNOLLY, AJ ;
COUGHLIN, SR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) :2752-2756
[4]   Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes [J].
Chiarelli, F ;
Cipollone, F ;
Mohn, A ;
Marini, M ;
Iezzi, A ;
Fazia, M ;
Tumini, S ;
De Cesare, D ;
Pomilio, M ;
Pierdomenico, SD ;
Di Gioacchino, M ;
Cuccurullo, F ;
Mezzetti, A .
DIABETES CARE, 2002, 25 (10) :1829-1834
[5]   Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury [J].
Chow, F ;
Ozols, E ;
Nikolic-Paterson, DJ ;
Atkins, RC ;
Tesch, GH .
KIDNEY INTERNATIONAL, 2004, 65 (01) :116-128
[6]   Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice [J].
Chow, FY ;
Nikolic-Paterson, DJ ;
Ozols, E ;
Atkins, RC ;
Rollin, BJ ;
Tesch, GH .
KIDNEY INTERNATIONAL, 2006, 69 (01) :73-80
[7]   Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/1pr lupus-prone mice [J].
de Lema, GP ;
Maier, H ;
Franz, TJ ;
Escribese, M ;
Chilla, S ;
Segerer, S ;
Camarasa, N ;
Schmid, H ;
Banas, B ;
Kalaydjiev, S ;
Busch, DH ;
Pfeffer, K ;
Mampaso, F ;
Schlöndorff, D ;
Luckow, B .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (12) :3592-3601
[8]   Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury [J].
Furuichi, K ;
Wada, T ;
Iwata, Y ;
Kitagawa, K ;
Kobayashi, K ;
Hashimoto, H ;
Ishiwata, Y ;
Tomosugi, N ;
Mukaida, N ;
Matsushima, K ;
Egashira, K ;
Yokoyama, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04) :1066-1071
[9]   CCR2 signaling contributes to ischemia-reperfusion injury in kidney [J].
Furuichi, K ;
Wada, T ;
Iwata, Y ;
Kitagawa, K ;
Kobayashi, KI ;
Hashimoto, H ;
Ishiwata, Y ;
Asano, M ;
Wang, H ;
Matsushima, K ;
Takeya, M ;
Kuziel, WA ;
Mukaida, N ;
Yokoyama, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (10) :2503-2515
[10]   THE ROLE OF MACROPHAGES IN DIABETIC GLOMERULOSCLEROSIS [J].
FURUTA, T ;
SAITO, T ;
OOTAKA, T ;
SOMA, J ;
OBARA, K ;
ABE, K ;
YOSHINAGA, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (05) :480-485